证券代码:600664 证券简称:哈药股份 编号:临 2023-056 哈药集团股份有限公司 关于分公司参与全国药品集中采购拟中标的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2023年11月6日，哈药集团股份有限公司（以下简称"公司"）分 公司哈药集团制药总厂（以下简称"哈药总厂"）参加了国家组织药 品联合采购办公室（以下简称"联采办"）组织的第九批全国药品集 中采购的投标工作，哈药总厂产品注射用盐酸头孢替安拟中标本次集 中采购。现就相关情况公告如下： | 中标 | 药品 | | 规格 | 拟中 标价 | 拟中 | 拟供应 | | 采购周 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 企业 | 名称 | 适应症 | 包装 | | 标数 | | | 期 | | | | | | 格（元 /支） | 量 | 省（区） | | | | | | 用于对本品敏感的葡萄球菌属、链 | | | | | | | | | | 球菌属（肠球菌除外）、肺炎球菌、 | ...

证券代码:600664 证券简称:哈药股 份 编号:临 2023-055 哈药集团股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担 法律责任。 重要内容提示： 哈药集团股份有限公司（以下简称"公司"）已于 2023 年 10 月 27 日发布公司 2023 年第三季度报告，为便于广大投资者更全面深入 地了解公司 2023 年第三季度经营成果、财务状况，公司计划于 2023 年 11 月 09 日下午 15:00-16:00 在全景网举办 2023 年第三季度业绩 说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会将采用网络远程的方式举行，公司将针对2023 年第三季度的经营成果及财务指标的具体情况与投资者进行互动交 流和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回 会议召开时间：2023 年 11 月 09 日(星期四) 下午 15:00-16:00 会议召开地点：全景网"投资者关系互动平台"（https://ir.p5w.net） 会议召开方式： ...

Financial Performance - The company's operating revenue for Q3 2023 reached CNY 3,790,463,897.95, representing a year-on-year increase of 6.03%[4] - Net profit attributable to shareholders for Q3 2023 was CNY 107,788,860.25, a significant increase of 213.43% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 91,036,057.00, reflecting a remarkable growth of 566.18% year-on-year[4] - The net profit attributable to shareholders for the first three quarters of 2023 was CNY 290,501,340.84, an increase of 85.72% year-on-year[4] - Total operating revenue for the first three quarters of 2023 reached CNY 11,493,851,773.09, a 15.06% increase from CNY 9,990,557,604.43 in the same period of 2022[16] - Net profit for the third quarter of 2023 was CNY 348,156,436.62, up 76.06% from CNY 197,871,918.72 in the previous year[17] - Basic earnings per share for Q3 2023 were CNY 0.04, up 300% year-on-year, while diluted earnings per share also stood at CNY 0.04[4] - Earnings per share for the third quarter of 2023 were CNY 0.12, compared to CNY 0.06 in the same quarter of 2022[18] - The company's total comprehensive income for the third quarter of 2023 was CNY 346,964,963.22, compared to CNY 195,225,557.07 in the same quarter of 2022[18] Cash Flow - The net cash flow from operating activities for the year-to-date period was CNY 805,517,961.21, an increase of 460.27% compared to the previous year[4] - Cash inflow from operating activities for the first three quarters of 2023 reached approximately ¥11.99 billion, a 22.7% increase from ¥9.75 billion in the same period of 2022[19] - Net cash flow from operating activities in Q3 2023 was approximately ¥805.52 million, significantly up from ¥143.77 million in Q3 2022, marking a growth of 460.5%[20] - The company's cash flow from operating activities for the first three quarters of 2023 was impacted by an increase in cash payments for goods and services, which rose to approximately ¥8.08 billion from ¥6.96 billion in the previous year, an increase of 16.1%[19] - Total cash outflow from operating activities in Q3 2023 was approximately ¥11.19 billion, compared to ¥9.61 billion in Q3 2022, reflecting a 16.5% increase[20] Assets and Liabilities - Total assets as of the end of Q3 2023 amounted to CNY 13,918,035,147.14, a 3.59% increase from the end of the previous year[5] - As of September 30, 2023, total current assets amount to ¥10,192,567,448.13, an increase from ¥9,559,632,007.81 at the end of 2022, representing a growth of approximately 6.6%[14] - Total liabilities as of the end of the third quarter of 2023 amounted to CNY 8,615,181,237.08, an increase from CNY 8,484,927,244.36 at the end of the previous year[16] - Total liabilities include short-term borrowings of ¥1,803,791,998.09, down from ¥1,932,960,236.62[14] - The company's total equity increased to CNY 5,302,853,910.06 in the third quarter of 2023, compared to CNY 4,951,053,669.26 in the same period of 2022[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 101,606[10] - The largest shareholder, Harbin Pharmaceutical Group Co., Ltd., holds 1,173,237,023 shares, accounting for 46.54% of total shares[10] Research and Development - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[12] - Research and development expenses for the first three quarters of 2023 were CNY 67,231,906.97, down from CNY 78,058,987.04 in the same period of 2022[16] Strategic Initiatives - The company has implemented a new brand strategy and product optimization to meet consumer demand for health products, contributing to revenue growth[7] - The company plans to enhance brand awareness and market share through increased promotional investments and online sales channel development[7] Non-Recurring Gains - Non-recurring gains for Q3 2023 included government subsidies totaling CNY 17,842,958.16, which positively impacted the financial results[6] Future Outlook - Future outlook and performance guidance were not explicitly mentioned in the available documents[12]

证券代码:600664 证券简称:哈药股份 编号:临2023-054 1、公司第三季度报告的编制和审议程序符合法律、法规、《公司章程》 和公司内部管理制度的规定； 2、公司第三季度报告的内容符合中国证监会和上海证券交易所的各项规 定，所包含的信息能从各个方面真实地反映公司 2023 年第三季度的经营和财 务状况，不存在任何虚假记载、误导性陈述或者重大遗漏； 3、在本意见提出前，未发现参与第三季度报告编制和审议的人员有违反 保密规定、内幕交易或其他违反法律法规的行为。 特此公告。 哈药集团股份有限公司 九届二十一次监事会决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 哈药集团股份有限公司（以下简称"公司"）第九届监事会第二十一次会 议以书面方式发出通知，于 2023 年 10 月 26 日以通讯表决方式召开。会议 应到监事 3 人，实到监事 3 人，会议召开符合《中华人民共和国公司法》（以 下简称"《公司法》"）和《公司章程》的有关规定。会议由监事会主席边科先 生主持，会议审议通过了《公司 2023 年第三季度报告》（同 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 哈药集团股份有限公司（以下简称"公司"）第九届董事会第三十九 次会议以书面方式发出通知，于 2023 年 10 月 26 日以通讯表决方式召开。 会议应参加董事 8 人，实际参加董事 8 人，会议召开符合《中华人民共和 国公司法》和《公司章程》的有关规定，会议审议通过了《2023 年第三 季度报告》（同意 8 票，反对 0 票，弃权 0 票） 经审议，公司董事会认为：公司 2023 年第三季度报告的编制符合相 关法律法规及《公司章程》的有关规定，报告真实、准确、完整地反映了 公司 2023 年第三季度的财务状况和经营情况，不存在虚假记载、误导性 陈述或重大遗漏。 证券代码:600664 证券简称:哈药股份 编号:临 2023-053 哈药集团股份有限公司 九届三十九次董事会决议公告 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披 露的公司 2023 年第三季度报告。 特此公告。 哈药集团股份有限公司董事会 二○二三年十月二十七日 1 ...

哈药集团股份有限公司（以下简称"公司"）董事会近日收到独 立董事潘广成先生递交的书面辞职报告。潘广成先生因在公司连续担 任独立董事职务满六年，根据《上市公司独立董事管理办法》等有关 规定，潘广成先生申请辞去公司第九届董事会独立董事及第九届董事 会提名委员会主任委员、战略决策委员会委员职务，辞职后不再在本 公司担任任何职务。截至本公告披露之日，潘广成先生未持有公司股 票，不存在应当履行而未履行的承诺事项。 根据《公司法》及《公司章程》等相关规定，潘广成先生辞职未 导致公司独立董事人数少于董事会人数的三分之一，亦未导致公司董 事会人数低于法定人数。公司董事会将按照规定，尽快完成董事补选 工作。 证券代码:600664 证券简称:哈药股 份 编号:临 2023-052 哈药集团股份有限公司 关于独立董事辞职的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 潘广成先生在任职期间恪尽职守、勤勉尽责，积极履行各项董事 职责，为公司健康发展和规范运作发挥了积极作用，公司董事会对潘 广成先生为公司发展所做出的贡献表示衷心感谢！ 特此公告。 ...

哈药集团股份有限公司 关于 2021 年股票期权与限制性股票激励计划 2023 年第三季度自主行权结果暨股份变动的公告 2、自 2023 年 7 月 3 日至 2023 年 9 月 28 日期间，股权激励计划行权并完成 过户登记 0.3 万份，均属于第一次预留授予期权，占第一次预留授予部分的第一 个行权期可行权股票期权总量的 0.33%。截止 2023 年 9 月 28 日，第一次预留授 予部分的股票期权第一个行权期累计行权并完成过户登记 42.7 万份，占可行权 股票期权总量的 46.92%。 证券代码:600664 证券简称:哈药股份 编号:临 2023-051 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次行权股票数量：哈药集团股份有限公司（以下简称"公司"）2021 年 股票期权与限制性股票激励计划（以下简称"本次股权激励计划"）在 2023 年第 三季度期间，公司股票期权已完成行权且股份过户登记 0.3 万份，均属于第一次 预留授予期权。 1、第一次预留授予部分的股票期权第一个行权期可行权股票期权 ...

哈药集团股份有限公司 2023 年 1-9 月主要经营数据预告的公告 证券代码:600664 证券简称:哈药股 份 编号:临 2023-050 公司本次经营业绩预计数据系公司基于自身专业判断进行的初步 测算，未经注册会计师审计，仅作为阶段性财务数据供投资者参考， 不能以此推算公司全年业绩情况，具体准确的财务数据以公司后续披 露的2023年第三季度报告为准，敬请广大投资者理性投资，注意投资 风险。 特此公告。 哈药集团股份有限公司董事会 二○二三年九月二十七日 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、2023年1-9月主要经营数据 哈药集团股份有限公司（以下简称"公司"）预计2023年1-9月营 业收入为108.90亿元到126.10亿元，较上年同期增长9.01%到26.22%； 预计2023年1-9月归属于上市公司股东的净利润为2.25亿元到3.00亿 元，较上年同期增长43.85%到91.80%。 二、风险提示 ...

关于分公司获得《药品生产许可证》的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，哈药集团股份有限公司（以下简称"公司"）分公司哈药 集团技术中心（以下简称"技术中心"）收到黑龙江省药品监督管理 局颁发的《药品生产许可证》，现就相关情况公告如下： 一、《药品生产许可证》的主要内容 企业名称：哈药集团技术中心 许可证编号：黑 20230025 分类码：Ah 注册地址：哈尔滨市利民开发区利民西四大街 68 号 证券代码:600664 证券简称:哈药股份 编号:临 2023-049 哈药集团股份有限公司 日常监督管理机构：黑龙江省药品监督管理局 有效期至：2028 年 8 月 2 日 生产地址和生产范围：哈尔滨市利民开发区利民西四大街 68 号： 口服混悬剂 二、对上市公司的影响及风险提示 本次技术中心首次获得《药品生产许可证》，用于研发口服混悬 剂仿制药注册申报。截至本公告日，开发的口服混悬剂仿制药处于生 物等效性临床试验阶段，根据药品法规监管要求，尚需取得药品批准 文号及通过 GMP 符合性检查后方可进行商业化生产，本 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached CNY 7.703 billion, representing a year-on-year increase of 20.07%[19] - The net profit attributable to shareholders for the same period was CNY 182.71 million, up 49.73% compared to the previous year[19] - The net cash flow from operating activities increased significantly by 221.76%, amounting to CNY 531.46 million[19] - The basic earnings per share rose to CNY 0.07, reflecting a growth of 40.00% year-on-year[20] - The net profit attributable to shareholders reached 183 million RMB, representing a year-on-year increase of 49.73%[22] - The pharmaceutical commercial segment achieved revenue of CNY 5,275.22 million, a year-on-year increase of 14.57%, and net profit attributable to shareholders of CNY 153.34 million, up 44.81%[53] - The gross margin for the pharmaceutical commercial segment was 9.37%, an increase of 0.33% year-on-year[53] - The total comprehensive income for the first half of 2023 was CNY 220,059,515.47, an increase of 51.06% from CNY 145,592,026.94 in the previous year[153] Assets and Liabilities - The company’s total assets at the end of the reporting period were CNY 13.735 billion, a 2.22% increase from the end of the previous year[19] - The net assets attributable to shareholders increased by 4.28% to CNY 4.516 billion[19] - The company's total liabilities were CNY 8,559,656,817.08, slightly up from CNY 8,484,927,244.36, marking an increase of about 0.9%[142] - The company's short-term borrowings decreased by 7.82% to CNY 1,781,727,447.21, reflecting a strategic reduction in financing scale[65] - The total equity of the company was CNY 5,174,012,147.23, slightly down from CNY 5,051,053,669.26, reflecting a decrease of about 2.4%[142] Market and Product Development - The pharmaceutical commercial sector saw growth in both wholesale and retail businesses, driven by an expanded product range and enhanced sales management[21] - The company has strengthened its collaboration with medical institutions, increasing the sales proportion of high-quality customers[21] - The introduction of DTP products and improvement in pharmacy service capabilities contributed to the growth of specialized pharmacy sales[21] - The pharmaceutical industrial segment achieved breakthroughs in respiratory and gastrointestinal products, contributing to overall sales growth[22] - The company holds 1,802 drug approvals and 100 health product approvals, focusing on major therapeutic areas such as infection, chronic diseases, and respiratory health[29] - The company is focusing on the development of key products in the anti-infection and respiratory medication sectors, aiming to enhance brand influence and market competitiveness[56] - The company plans to focus on the health product sector, with multiple health products expected to be launched in the second half of the year[59] Operational Efficiency and Strategy - The company actively optimized its product mix and supply chain management, improving operational efficiency and gross margin[22] - The company implemented a clear product channel strategy, enhancing product penetration and network coverage across various channels[22] - The company is transitioning to an operational control model, implementing a comprehensive budget management system to optimize resource allocation and enhance strategic execution[41] - The company has established a comprehensive product lifecycle management system to optimize procurement, production, and inspection cycles, effectively shortening supply cycles[48] - The company has implemented lean production principles to improve product quality and control production costs, achieving a 46% reduction in process nodes through procurement optimization[48] Research and Development - The company is focused on R&D in chemical synthesis, modern traditional Chinese medicine, and biotechnology, supported by six national high-tech enterprises and various provincial research centers[37] - The company is actively developing over 20 products in research, focusing on therapeutic areas such as digestion and chronic diseases, with several products undergoing consistency evaluation[46] - The company aims to enhance product competitiveness by leveraging consumer demand and launching new products in response to market opportunities[44] Environmental and Social Responsibility - The company has established a quality assurance system aligned with international standards, ensuring product quality exceeds national legal requirements[38] - The company has implemented a carbon reduction strategy, including a pilot photovoltaic power generation project and measures to optimize production efficiency, resulting in reduced production costs and energy consumption[104] - The company donated materials worth CNY 1.4068 million through its charity foundation, benefiting nearly 98,000 people during the reporting period[105] - The company has established a comprehensive environmental protection responsibility system and has set annual environmental management goals and indicators, which are regularly assessed[101] Shareholder and Capital Management - The company’s total share capital decreased from 2,525,877,076 shares to 2,523,478,076 shares due to the repurchase and cancellation of 2,399,000 restricted shares[117] - The company reported a total of 1,327,000 newly unrestricted shares during the reporting period[123] - The company continues to monitor shareholder dynamics and the impact of stock repurchase on overall shareholder value[129] - The total equity attributable to the parent company reached 4,951,053.6 million, with a significant increase compared to the previous period[164] Future Outlook - The company plans to expand its market presence and invest in new product development to sustain growth in the upcoming quarters[1] - Future guidance indicates a projected revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion efforts[166] - The company is exploring potential mergers and acquisitions to enhance its market position and operational capabilities[166]